Key Highlights

  • DataMeds AI (NASDAQ:MEDS) traded at USD 2.06, down 5.76%, in pre-market trading on Tuesday, October 27, 2026, after Datavault AI announced a non-binding letter of intent for a 19.9% equity stake tied to an expanded technology licence.
  • For the quarter ended June 30, 2026, net revenues were USD 1,779,860 against USD 7,790,865 a year earlier, and the net loss was USD 18,363,225, or USD 7.13 per share.
  • Cash was USD 2,456,373 at June 30, 2026, against total liabilities of USD 52,263,663 and a stockholders' deficit of USD 19,504,231, with USD 6.5 million of new funding raised in June 2026.
  • The pre-market quote is a thinly traded snapshot, the letter of intent is non-binding, and the company completed a 1-for-50 reverse split in May 2026.

The Pre-Market Move and Its Catalyst

DataMeds AI (NASDAQ:MEDS), formerly Wellgistics Health, an integrated healthcare company combining pharmacy services, telemedicine and artificial intelligence platforms, traded at USD 2.06, down 5.76%, in pre-market trading on Tuesday, October 27, 2026. The most recent company-specific news was an announcement dated Thursday, October 22, 2026 that Datavault AI signed a non-binding letter of intent to acquire a 19.9% equity stake in DataMeds AI in consideration of an expanded technology licence. This account relies on the announcement titles rather than the full text. A non-binding letter creates no obligation to close, and the decline appears consistent with profit-taking and thin pre-market liquidity. The snapshot can change before the open at 9:30 a.m. ET.

How the Latest Results Frame the Move

The company's release of Monday, August 17, 2026 reported net revenues of USD 1,779,860 for the second quarter of 2026, against USD 7,790,865 a year earlier, although revenue rose 14% from the first quarter. The net loss was USD 18,363,225, or USD 7.13 per share, and the loss from operations was USD 7,345,054. Cash was USD 2,456,373 at June 30, 2026, against USD 42,571 at December 31, 2025, while total liabilities were USD 52,263,663 against total assets of USD 32,759,432. The company raised USD 6.5 million in June 2026 and restructured USD 14.5 million of debt. The sharp annual revenue decline and the stockholders' deficit explain why equity-linked transactions weigh heavily on the share price.

Risks and What to Watch

The bull reading rests on the equity interest and expanded licence from Datavault AI, the debt restructuring and planned product launches, including a consumer app with an alumni health organisation and a medical food named Forzet. The bear reading rests on the revenue fall of more than 77% from the prior-year quarter (simple arithmetic on two published figures), the stockholders' deficit and the non-binding status of the letter. Named risks include dilution from preferred equity swaps and new issuance, Nasdaq listing compliance and execution of the pending Datavault transaction. Lock-up agreements covering 1,533,930 common shares, about 49% of shares outstanding, were scheduled to run at least 90 more days from the release. Investors should watch the Wednesday, October 28, 2026 Fed decision, a definitive Datavault agreement and the closing expected in the second half of 2026.

Where Things Stand

The answer is that DataMeds AI (NASDAQ:MEDS) appears to have fallen 5.76% pre-market as the market weighs a non-binding Datavault AI equity letter against weak revenue and a stockholders' deficit, with thin liquidity amplifying the move. The key number is the second-quarter net loss of USD 18,363,225. The next catalysts are the Fed decision on Wednesday, October 28, 2026, a definitive Datavault agreement and the third-quarter 2026 results release. Pre-market prices are snapshots and can change, and this is not investment advice.